Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × selinexor × Sarcoma × Clear all

Phase

Phase 1 6 Phase 2 2 Phase 1/2 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Doxorubicin 5 Radiotherapy 3 Temozolomide 2 Radiation 2 Imatinib Mesylate 2 Ifosfamide 2 Drug Therapy 2 veliparib 1 selinexor 1 regorafenib 1 pirarubicin 1 pazopanib 1 niraparib 1 liposomal doxorubicin 1 fludarabine phosphate 1 dostarlimab 1 brigimadlin 1 apatinib 1 anlotinib 1 Zoledronic Acid 1 Whole-Body Irradiation 1 Triptorelin Pamoate 1 Trabectedin 1 Thiotepa 1 Sugars 1 PTC596 1 Nivolumab 1 Methotrexate 1 Melphalan 1 Magnetic Resonance Spectroscopy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡